Phase 3 clinical trial of Diroximel fumarate for treatment of RRMS yields positive top-line results
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the(http://of thecompany of Alkermes and Biogen announced positive top-line resultsa Phase 3 clinicaltrial (http:// for the treatment of recurrent recurrent multiple sclerosis (RRMS)Compared to dimethyl fumarate, the new oral fumarate diroximel fumarate with a unique chemical structure is comparable in efficacy and has better gastrointestinal (gastrointestinal, GI) safety and toleranceAbout Diroximel fumarate
Diroximel fumarate is a precursor to oral fumarateIt can be quickly converted into methylene sulprates in the bodyMomaracid monomethylesters can reduce damage from oxidative stress by activating a transcription factor called Nrf2Diroximel fumarate is currently under review by the u.SFDA(http://and is expected to receive a response in the fourth quarter of this yearon EVOLVE-MS-2
EVOLVE-MS-2 is a randomized double-blind, active-controlled, 5-week Phase 3 clinical trial designed to assess GI tolerance, including duration and severity, in PATIENTs with RRMS compared to Tecfidera In this trial, the proportion of patients who withdrew from the trial because of adverse events (AE) was 1.6% in the diroximel fumarate group and 6.0% in the Tecfidera group Of these, the proportion of patients who withdrew from the trial due to GI adverse events was 0.8% in the diroximel fumarate group and 4.8% in the Tecfidera group Data show that the side effects of diroximel fumarate are significantly lower than that of Tecfidera
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
